Physician profile
Amy M Strobbe
NPI 1801862487
$9,752.43
in general payments reported to CMS, 2019-2025
43 companies · $1,767 in 2025
The $1,767 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $437 · 2021: $1,255 · 2022: $1,742 · 2023: $1,918 · 2024: $1,759 · 2025: $1,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,346 · Education: $97.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,345.81 |
| Education | $97.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,081.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $912.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $791.91 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $756.27 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $583.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $456.64 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.54 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $428.85 | 2019-2024 | Xarelto |
| Allergan, INC. | $325.59 | 2019-2022 | |
| Amgen INC. | $292.44 | 2019-2024 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $286.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $276.58 | 2019-2025 | |
| Eisai INC. | $248.66 | 2021-2022 | |
| Astellas Pharma US INC | $224.00 | 2020-2025 | Veozah |
| Dexcom, INC. | $172.57 | 2022-2023 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Strobbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.